NCT01606566 - A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

August 31, 2015

Study Completion Date

January 31, 2016

Conditions

Recurrent Head and Neck CancerCarcinoma, Squamous Cell of Head and Neck

Interventions

DRUG

Amphinex induced PCI of bleomycin

Intravenous administration of 0.25 mg/kg Amphinex (day 0) followed by intravenous administration of bleomycin (15000 IU/m2, day 4) and laser light application (3 hours (+/- 1 hour) after bleomycin administration).

Trial Locations (10)

10117

Charité Comprehensive Cancer Center, Berlin

23538

Universitätsklinikum Schleswig-Holstein, Lübeck

44093

CHU de Nantes Hôtel Dieu, Nantes

45147

Universitätsklinikum Essen, Essen

Unknown

Centre Alexis Vautrin (CAV)-Nancy Université, Nancy

Ludwig Maximilian University Munich, München

The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam

Szpital Specjalistyczny w Brzozowie, Brzozów

University College London Hospital, London

08660

Institute of Oncology, Vilnius University, Vilnius